文献速递肝病消化道肿瘤与早癌

新型多靶点血液检测对早期肝细胞癌高敏感性的验证

Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-08-13

该国际多中心病例对照研究建立了多靶点HCC血液检测(mt-HBT)算法,该算法整合甲基化生物标志物(HOXA1、TSPYL5、B3GALT6)、AFP和性别。在独立验证队列中,mt-HBT对早期HCC的敏感性为82%,特异性为87%,显著高于AFP(40%)和GALAD(71%)。

要点

  • mt-HBT对早期HCC敏感性82%,显著优于AFP(40%)和GALAD(71%)。
  • 验证队列总体敏感性88%,特异性87%。
  • AFP和GALAD在相应 cut-off 下特异性更高(100%和93%)。

核心结论

  • mt-HBT可能显著改善接受HCC监测患者的早期HCC检测。

研究设计与样本

  • 国际多中心病例对照研究,包括算法开发与临床验证两部分。
  • 研究对象为肝硬化或慢性乙型肝炎患者,HCC病例按AASLD标准诊断,对照按年龄和肝病病因匹配。

主要发现

  • 算法开发队列:136例HCC(60%早期)和404例对照,mt-HBT对早期HCC敏感性72%,特异性88%。
  • 独立验证队列:156例HCC(50%早期)和245例对照,mt-HBT总体敏感性88%,早期敏感性82%,特异性87%。
  • 验证队列中早期敏感性显著高于AFP≥20 ng/mL(40%;P < .0001)和GALAD≥-0.63(71%;P = .03)。
  • AFP和GALAD在相应cut-off下特异性更高,分别为100%和93%。

关键数值与推荐

  • mt-HBT算法包含甲基化生物标志物HOXA1、TSPYL5、B3GALT6、AFP和性别。
  • 验证队列中mt-HBT早期HCC敏感性82%,特异性87%。
  • AFP≥20 ng/mL早期敏感性40%,特异性100%。
  • GALAD≥-0.63早期敏感性71%,特异性93%。

临床怎么用

  • mt-HBT可作为接受HCC监测患者的血液检测选项,提高早期HCC检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Although biannual ultrasound surveillance with or without α-fetoprotein (AFP) testing is recommended for at-risk patients, sensitivity for early stage HCC, for which potentially curative treatments exist, is suboptimal. We conducted studies to establish the multitarget HCC blood test (mt-HBT) algorithm and cut-off values and to validate test performance in patients with chronic liver disease. METHODS: Algorithm development and clinical validation studies were conducted with participants in an international, multicenter, case-control study. Study subjects had underlying cirrhosis or chronic hepatitis B virus; HCC cases were diagnosed per the American Association for the Study of Liver Diseases criteria and controls were matched for age and liver disease etiology. Whole blood and serum were shipped to a central laboratory and processed while blinded to case/control status. An algorithm was developed for the mt-HBT, which incorporates methylation biomarkers (HOXA1, TSPYL5, and B3GALT6), AFP, and sex. RESULTS: In algorithm development, with 136 HCC cases (60% early stage) and 404 controls, the mt-HBT showed 72% sensitivity for early stage HCC at 88% specificity. Test performance was validated in an independent cohort of 156 HCC cases (50% early stage) and 245 controls, showing 88% overall sensitivity, 82% early stage sensitivity, and 87% specificity. Early stage sensitivity in clinical validation was significantly higher than AFP at 20 ng/mL or greater (40%; P < .0001) and GALAD (gender, age, Lens culinaris agglutinin-reactive AFP, AFP, and des-γ-carboxy-prothrombin score) of -0.63 or greater (71%; P = .03), although AFP and GALAD at these cut-off values had higher specificities (100% and 93%, respectively). CONCLUSIONS: The mt-HBT may significantly improve early stage HCC detection for patients undergoing HCC surveillance, a critical step to increasing curative treatment opportunities and reducing mortality. ClinicalTrials.gov number NCT03628651.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chalasani NP, Porter K, Bhattacharya A, et al. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2021. PMID: 34391922. doi:10.1016/j.cgh.2021.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。